Jessica M. Boyd, PhD, FCACB, DABCC(TC)

Associate Professor (Clinical), University of Utah School of Medicine

Specialties

• Urine drug screening
• Therapeutic drug monitoring
• Trace element testing

Education

• Doctorate Degree—Medical Sciences (Analytical and Environmental Toxicology), University of Alberta
• Fellowship—Clinical Chemistry, University of Calgary/Calgary Laboratory Services

Certification/Affiliations

• Fellow of the Canadian Academy of Clinical Biochemistry
• American Board of Clinical Chemistry (Toxicological Chemistry)
• American Association of Clinical Chemistry
• Canadian Society of Clinical Chemists
• International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Research Interests

• Urine drug screening
• Dried specimen analysis

Awards

• 2018 Canadian Society of Clinical Chemists Award for Innovation in Laboratory Medicine
• 2016 Laboratory Director Grant, Mass Spectrometry Applications in the Clinical Laboratory

Recent Publications

• McMillin GA, Morad AW, Boyd JM, et al. Biological testing and interpretation of laboratory results associated with detecting newborns with substance exposure. Clin Chem. 2024;70(7):934-947.
• Boyd JM, Kelly BN, McMillin GA. Prevalence of gabapentinoid and opioid copositives in a reference laboratory patient population. J Appl Lab Med. 2024;9(4):861-863.
• Merrigan SD, Yang YK, McMillin GA, et al. Detection of 41 drugs and metabolites in urine with internal hydrolysis control by liquid chromatography-tandem mass spectrometry. Methods Mol Biol. 2024;2737:229-247.
• Wickramarachchi, Boyd JM, Orton DJ. Biological variation in clozapine and metabolite reporting during therapeutic drug monitoring. Clin Chim Acta. 2022;531: 183-187.
• Kline GA, Boyd J, Hyrcza M, et al. Updated reference intervals for urine normetanephrine have no effect on test sensitivity but fewer false positives. Clin Biochem. 2022;99:17-19.
• Kline GA, Boyd J, Sadrzadeh HSM, et al. Inpatient measurements of urine metanephrines are indistinguishable from pheochromocytoma: retrospective cohort study. Am J Med. 2021;134(8):1039-1046.e3.
• Kline GA, Boyd J, Polzin B, et al. Properly collected plasma metanephrines excludes PPGL after false-positive screening tests. J Clin Endocrinol Metab. 2021;106(8):e2900-e2906.
• Qasrawi DO, Boyd JM, Sadrzadeh SMH. Measuring steroids from dried blood spots using tandem mass spectrometry to diagnose congenital adrenal hyperplasia. Clin Chim Acta. 2021;520:202-207.
• Leung AA, Pasieka JL, Hyrcza MD, et al. Epidemiology of pheochromocytoma and paraganglioma: population-based cohort study. Eur J Endocrinol. 2021;184(1):19-28. 
• Snozek CLH, Baskin LB, Boyd JM, et al. How can routine clinical laboratories keep up with the opioid crisis? Clin Chem. 2021;67(2):338-344.
• Kline GA, Boyd J, Leung AA, et al. Moderate renal impairment does not preclude the accuracy of 24-hour urine normetanephrine measurements for suspected pheochromocytoma. Clin Endocrinol. 2020;92(6):518-524.
• Kline GA, Boyd J, Leung AA, et al. Very high rate of false positive biochemical results when screening for phaeochromocytoma in a large undifferentiated population with variable indications for testing. Clin Biochem. 2020;77:26-31.